S. Bar‐Yehuda

1.3k total citations
19 papers, 1.1k citations indexed

About

S. Bar‐Yehuda is a scholar working on Physiology, Oncology and Immunology. According to data from OpenAlex, S. Bar‐Yehuda has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 5 papers in Oncology and 4 papers in Immunology. Recurrent topics in S. Bar‐Yehuda's work include Adenosine and Purinergic Signaling (11 papers), NF-κB Signaling Pathways (3 papers) and HIV Research and Treatment (2 papers). S. Bar‐Yehuda is often cited by papers focused on Adenosine and Purinergic Signaling (11 papers), NF-κB Signaling Pathways (3 papers) and HIV Research and Treatment (2 papers). S. Bar‐Yehuda collaborates with scholars based in Israel, United States and Italy. S. Bar‐Yehuda's co-authors include Pnina Fishman, Shira Cohen, Faina Barer, Avivit Ochaion, Lea Rath‐Wolfson, R. Patoka, Pier Andrea Borea, Stefania Gessi, Ziva Weisman and C. Moroz and has published in prestigious journals such as Journal of Hepatology, British Journal of Cancer and Biochemical Pharmacology.

In The Last Decade

S. Bar‐Yehuda

18 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Bar‐Yehuda Israel 14 723 430 180 172 110 19 1.1k
Józef Spychała United States 17 880 1.2× 722 1.7× 265 1.5× 181 1.1× 52 0.5× 36 1.6k
Gary P. Jamieson Australia 18 542 0.7× 546 1.3× 167 0.9× 438 2.5× 43 0.4× 31 1.3k
Stefan Dichmann Germany 17 499 0.7× 389 0.9× 131 0.7× 636 3.7× 20 0.2× 27 1.3k
Mark Griffiths United Kingdom 13 710 1.0× 584 1.4× 331 1.8× 147 0.9× 18 0.2× 18 1.5k
Felix Scheuplein United States 15 566 0.8× 431 1.0× 253 1.4× 506 2.9× 16 0.1× 23 1.4k
Norikatsu Mizumoto United States 11 222 0.3× 278 0.6× 151 0.8× 508 3.0× 23 0.2× 15 1.0k
Frederico S. Regateiro Portugal 14 185 0.3× 356 0.8× 270 1.5× 428 2.5× 13 0.1× 41 1.4k
Cynthia Mueller United States 13 117 0.2× 248 0.6× 147 0.8× 711 4.1× 28 0.3× 19 1.2k
C C Liu United States 12 179 0.2× 324 0.8× 104 0.6× 598 3.5× 17 0.2× 18 1.1k
Erika Ortolan Italy 18 730 1.0× 483 1.1× 353 2.0× 470 2.7× 22 0.2× 31 1.6k

Countries citing papers authored by S. Bar‐Yehuda

Since Specialization
Citations

This map shows the geographic impact of S. Bar‐Yehuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Bar‐Yehuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Bar‐Yehuda more than expected).

Fields of papers citing papers by S. Bar‐Yehuda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Bar‐Yehuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Bar‐Yehuda. The network helps show where S. Bar‐Yehuda may publish in the future.

Co-authorship network of co-authors of S. Bar‐Yehuda

This figure shows the co-authorship network connecting the top 25 collaborators of S. Bar‐Yehuda. A scholar is included among the top collaborators of S. Bar‐Yehuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Bar‐Yehuda. S. Bar‐Yehuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Geva, Ronny, et al.. (2024). Movement Coordination’s Link with Common Ground During Dyadic Peer Discourse in Typically Developing and Autistic Speakers. Journal of Autism and Developmental Disorders. 56(4). 1325–1338. 1 indexed citations
2.
Bauminger‐Zviely, Nirit, et al.. (2019). Communicating Without Words: School-Based RCT Social Intervention in Minimally Verbal Peer Dyads with ASD. Journal of Clinical Child & Adolescent Psychology. 49(6). 837–853. 7 indexed citations
3.
Stemmer, Salomon M., Ofer Benjaminov, Michael H. Silverman, et al.. (2012). 1411 CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY. Journal of Hepatology. 56. S555–S555. 4 indexed citations
4.
Cohen, Shira, Salomon M. Stemmer, Avivit Ochaion, et al.. (2010). CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver. Journal of Cellular Physiology. 226(9). 2438–2447. 73 indexed citations
5.
Ochaion, Avivit, S. Bar‐Yehuda, Shira Cohen, et al.. (2009). The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease. Cellular Immunology. 258(2). 115–122. 104 indexed citations
6.
Bar‐Yehuda, S., Lea Rath‐Wolfson, Luis Del Valle, et al.. (2009). Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis & Rheumatism. 60(10). 3061–3071. 107 indexed citations
7.
Borea, Pier Andrea, Stefania Gessi, S. Bar‐Yehuda, & Pnina Fishman. (2009). A3 Adenosine Receptor: Pharmacology and Role in Disease. Handbook of experimental pharmacology. 297–327. 47 indexed citations
8.
Fishman, Pnina, S. Bar‐Yehuda, Michael Synowitz, et al.. (2009). Adenosine Receptors and Cancer. Handbook of experimental pharmacology. 399–441. 123 indexed citations
9.
Ochaion, Avivit, S. Bar‐Yehuda, Shira Cohen, et al.. (2008). The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochemical Pharmacology. 76(4). 482–494. 60 indexed citations
10.
Fishman, Pnina, Kenneth A. Jacobson, Avivit Ochaion, Shira Cohen, & S. Bar‐Yehuda. (2007). The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy. Immunology Endocrine & Metabolic Agents - Medicinal Chemistry. 7(4). 298–303. 19 indexed citations
11.
Rath‐Wolfson, Lea, S. Bar‐Yehuda, Lea Madi, et al.. (2006). IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.. PubMed. 24(4). 400–6. 53 indexed citations
12.
Carey, Wayne, Steve Warrington, William Kerns, et al.. (2004). Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. International Journal of Clinical Pharmacology and Therapeutics. 42(10). 534–542. 55 indexed citations
13.
Ohana, Gil, S. Bar‐Yehuda, Lea Madi, et al.. (2003). Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. British Journal of Cancer. 89(8). 1552–1558. 76 indexed citations
14.
Fishman, Pnina, S. Bar‐Yehuda, Gil Ohana, et al.. (2000). Adenosine acts as an inhibitor of lymphoma cell growth. European Journal of Cancer. 36(11). 1452–1458. 81 indexed citations
15.
Merimsky, Ofer, et al.. (1998). Mononuclear cells release low molecular weight factors with anti-cancer activity: A lower level of production by cells of cancer patients.. International Journal of Oncology. 12(4). 921–5. 1 indexed citations
16.
Bar‐Yehuda, S., et al.. (1998). Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth.. PubMed. 58(14). 3181–7. 63 indexed citations
17.
Bentwich, Zvi, Ziva Weisman, C. Moroz, S. Bar‐Yehuda, & Alexander Kalinkovich. (1996). Immune dysregulation to Ethiopian immigrants in Israel: relevance to helminth infections?. Clinical & Experimental Immunology. 103(2). 239–243. 113 indexed citations
18.
Bentwich, Zvi, et al.. (1995). Pending problem of "silent" human immunodeficiency virus infection.. PubMed. 41(3). 345–50. 1 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Józef Spychała Breakdown of academic impact, for papers by Gary P. Jamieson Breakdown of academic impact, for papers by Stefan Dichmann Breakdown of academic impact, for papers by Mark Griffiths Breakdown of academic impact, for papers by Felix Scheuplein Breakdown of academic impact, for papers by Norikatsu Mizumoto Breakdown of academic impact, for papers by Frederico S. Regateiro Breakdown of academic impact, for papers by Cynthia Mueller Breakdown of academic impact, for papers by C C Liu Breakdown of academic impact, for papers by Erika Ortolan
Rankless by CCL
2026